Prospective trial of efficacy and safety of ondansetron and fluoxetine in patients with obstructive sleep apnea syndrome

Sleep

Volumn 33, Issue 7, 2010, Pages 982-989

  Prasad, Bharati ^a   Radulovacki, Miodrag ^a   Olopade, Christopher ^a   Herdegen, James J ^a   Logan, Thomas ^b   Carley, David W ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b BIOCOMPATIBLES UK LTD   (United Kingdom)

Author keywords

Apnea; Clinical trial; Drug treatment; Fluoxetine; Ondansetron; OSA; Placebo controlled; Randomized

Indexed keywords

FLUOXETINE; ONDANSETRON; PLACEBO; SEROTONIN ANTAGONIST;

ADULT; APNEA HYPOPNEA INDEX; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; NONREM SLEEP; OXIMETRY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; REM SLEEP; SLEEP APNEA SYNDROME;

EID: 77954357784     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.1093/sleep/33.7.982     Document Type: Article

References (37)

1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. New Engl J Med 1993;328:1230-5.
2. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:1217-39.
3. Marshall NS, Wong KK, Liu PY, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008;31:1079-85.
4. Harsch IA, Schahin SP, Radespiel-Troger M, et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004;169:156-62.
5. Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med 2001;163:344-8.
6. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046-53.
7. Dorkova Z, Petrasova D, Molcanyiova A, Popovnakova M, Tkacova R. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 2008;134:686-92.
8. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thoracic Soc 2008;5:173-8.
9. Smith I, Lasserson TJ, Wright J. Drug therapy for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006:CD003002.
10. Heym J, Steinfels GF, Jacobs BL. Activity of serotonin-containing neurons in the nucleus raphe pallidus of freely moving cats. Brain Res 1982;251:259-76.
11. Ling L. Serotonin and NMDA receptors in respiratory long-term facilitation. Respir Physiol Neurobiol 2008;164:233-41.
12. Valic M, Pecotic R, Dogas Z. Phrenic nerve activity is enhanced by 5-HT1A receptor agonist 8-OH-DPAT in spontaneously breathing anesthetized rats. J Physiol Pharmacol 2008;59:17-25.
13. Fenik P, Veasey SC. Pharmacological characterization of serotonergic receptor activity in the hypoglossal nucleus. Am J Respir Crit Care Med 2003;167:563-9.
14. Martin-Body RL, Grundy HR. Effects of neurotoxin-induced brainstem lesions on the respiratory responses of conscious rats. Clin Exp Pharmacol Physiol 1985;12:427-37.
15. Mahamed S, Mitchell GS. Simulated apnoeas induce serotonin-dependent respiratory long-term facilitation in rats. J Physiol 2008;586:2171-81.
16. Carley DW, Radulovacki M. Role of peripheral serotonin in the regulation of central sleep apneas in rats. Chest 1999;11:1397-401.
17. Mendelson WB, Maczaj M, Holt J. Buspirone administration to sleep apnea patients. J Clin Psychopharmacol 1991;11:71-2.
18. Kraiczi H, Hedner J, Dahlof P, Ejnell H, Carlson J. Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep 1999;22:61-7. (Pubitemid 29097899)
19. Hanzel DA, Proia NG, Hudgel DW. Response of obstructive sleep apnea to fluoxetine and protriptyline. Chest 1991;100:416-21.
20. Carley DW, Depoortere H, Radulovacki M. R-zacopride, a 5-HT3 antagonist/5-HT4 agonist, reduces sleep apneas in rats. Pharmacol Biochem Behav 2001;69:283-9. (Pubitemid 32566273)
21. Radulovacki M, Trbovic SM, Carley DW. Serotonin 5-HT3-receptor antagonist GR 38032F suppresses sleep apneas in rats. Sleep 1998;21:131-6. (Pubitemid 128470358)
22. Veasey SC, Chachkes J, Fenik P, Hendricks JC. The effects of ondansetron on sleep-disordered breathing in the English bulldog. Sleep 2001;24:155-60. (Pubitemid 32204191)
23. Stradling J, Smith D, Radulovacki M, Carley D. Effect of ondansetron on moderate obstructive sleep apnoea, a single night, placebo-controlled trial. J Sleep Res 2003;12:169-70.
24. Carley DW, Radulovacki M. Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat. Am J Respir Crit Care Med 1999;160:1824-9.
25. Carley DW, Olopade C, Ruigt GS, Radulovacki M. Efficacy of mirtazapine in obstructive sleep apnea syndrome. Sleep 2007;30:35-41. (Pubitemid 46095381)
26. Marshall NS, Yee BJ, Desai AV, et al. Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea. Sleep 2008;31:824-31.
27. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999;22:667-89.
28. EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 1992;15:173-84.
29. Blanco-Centurion CA, Salin-Pascual RJ. Extracellular serotonin levels in the medullary reticular formation during normal sleep and after REM sleep deprivation. Brain Res 2001;923:128-36.
30. Strecker RE, Thakkar MM, Porkka-Heiskanen T, Dauphin LJ, Bjorkum AA, McCarley RW. Behavioral state-related changes of extracellular sero- serotonin concentration in the pedunculopontine tegmental nucleus: a microdialysis study in freely moving animals. Sleep Res Online 1999;2:21-7.
31. Sood S, Raddatz E, Liu X, Liu H, Horner RL. Inhibition of serotonergic medullary raphe obscurus neurons suppresses genioglossus and diaphragm activities in anesthetized but not conscious rats. J Appl Physiol 2006;100:1807-21.
32. Sood S, Morrison JL, Liu H, Horner RL. Role of endogenous serotonin in modulating genioglossus muscle activity in awake and sleeping rats. Am J Respir Crit Care Med 2005;172:1338-47.
33. Matsumoto S. Effects of carotid Body chemoreceptor stimulation by 5-HT on phrenic nerve activity and ventilation in the rabbit. Arch Int Pharmacodyn Ther 1981;254:282-92. (Pubitemid 12198001)
34. Carley DW, Radulovacki M. Apnea suppression by ondansetron and fluoxetine alone and combined. Sleep 2005;28(Abstract Supplement):A12
35. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378-84.
36. Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol 2004;160:521-30.
37. Iber C A-IS, Chesson A, Quan SF. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. 1st ed. Westchester, IL: American Academy of Sleep Medicine, 2007.